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Abstract Previous electrophysiological work has demonstrated
expression of a voltage-gated Na+ channel (VGSC) specifically
in two highly metastatic prostatic epithelial tumour cell lines:
MAT-LyLu (rat) and PC-3 (human). However, the identity of
the channel(s) present was uncertain. The present study used a
combination of molecular biological techniques to demonstrate
that full-length skeletal muscle type 1 (SkM1) VGSC mRNA is
present in the mRNA pool of the MAT-LyLu cell line. mRNA
for this particular channel type was also expressed in the PC-3
cells. In situ hybridisation data suggested that the level and
pattern of rSkM1 mRNA expression were different in the
Dunning cells of markedly different metastatic potential.
Interestingly, the same type of mRNA was also detected in the
weakly metastatic counterparts of the cells : AT-2 (rat) and
LNCaP (human).
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1. Introduction
Voltage-gated Na channels (VGSCs) are well known to
play a crucial role in ‘excitable’ (nerve and muscle) cells where
they mediate a variety of functions, especially regenerative
conduction of impulses, and mechanisms of stimulation-secre-
tion and excitation-contraction coupling [1]. Interestingly, in-
creasing evidence suggests that VGSCs also occur in suppos-
edly ‘non-excitable’ cell types such as glia [2], lymphocytes [3],
osteoblasts [4], endothelia [5] and ¢broblasts [6]. In the latter
group of cells, however, the functional role of VGSCs is not
so well understood.
Physiologically and pharmacologically di¡erent VGSCs are
expressed di¡erentially during development and among tissue
types (reviewed in [7]). Nine di¡erent full-length K-subunit
cDNAs have so far been identi¢ed from a variety of excitable
tissue types in the rat alone [8^14]. Nevertheless, all cloned
VGSCs possess the same basic structural features: four mem-
brane-spanning pseudo-subunit domains containing multiple
potential K-helical transmembrane segments. Most cloned
VGSCs belong to the Nav1 subfamily.
Recently, we have found that VGSC activity occurs in the
highly metastatic prostatic carcinoma cell line (MAT-LyLu)
of the rat; in contrast, no such currents were detected electro-
physiologically in the related but weakly metastatic AT-2 cell
line [15]. A positive correlation was also found between Na
channel expression and invasiveness in numerous rat and hu-
man cell lines and transfected cells [16]. Furthermore, block-
age of VGSCs by tetrodotoxin (TTX) reduced the MAT-LyLu
cells’ invasiveness in vitro by up to 50% indicating strongly
that VGSC activity could contribute to the metastatic process
[15]. Broadly similar results were obtained from analogous
human cell lines: highly metastatic PC-3 and lowly metastatic
LNCaP cells [17]. Electrophysiological and pharmacological
experiments on the MAT-LyLu cells suggested that the
VGSC(s) expressed had properties consistent with those of
Nav1-type TTX-sensitive channels [18].
The main purpose of the present study was to use a molec-
ular biological approach to investigate further VGSC expres-
sion in the two rat model cell lines, and extend this to the
comparable human cells.
2. Materials and methods
2.1. Tissue culture
The MAT-LyLu and AT-2 cell lines were cultured using the pro-
tocol described in [15]. PC-3 and LNCaP cells were grown as in [17].
2.2. RNA extraction
For cloning and sequencing work, total RNA was extracted as
described in [19]. For Northern blots, which were carried out for
the rat tissues only, a di¡erent protocol was used. Brie£y, cells were
homogenised in a solution (‘A’), using an IKA homogeniser, such that
1 ml of solution was used per 0.1 g of tissue. Solution A consisted of
4 M guanidinium thiocyanate, 25 mM sodium citrate (pH 7.0), 0.5%
sarcosyl and 0.72% (v/v) L-mercaptoethanol. To this were added 2 M
sodium acetate, pH 4.0 (10% volume of solution A), phenol (equal
volume of solution A) and chloroform (20% volume of solution A).
After mixing and centrifugation, two isopropanol precipitates were
performed and the samples resuspended in sterile distilled water.
2.3. Cloning and sequencing
DNA was removed from all the extracts by digestion with DNase
and 5 Wg of the total RNA was used as the template for single-
stranded cDNA (sscDNA) synthesis (Superscript II, Gibco BRL).
For MAT-LyLu and AT-2 work, sscDNA synthesis was primed
with an oligo dT primer/adaptor (dTAdap), as described in [20].
VGSC cDNA was then ampli¢ed from the cDNA pool by PCR
(Taq DNA polymerase, Pharmacia Biotech) using four degenerate
primers (NA1, NA2, NA3, NA4; designed speci¢cally to amplify all
currently known Nav1-type VGSC cDNA sequences; Table 1) in con-
junction with the anchored 3P primer added during cDNA synthesis
(the 20mer section, ‘Adap’). PCR reactions were performed in a ¢nal
volume of 20 Wl under the following typical conditions: 94‡C for
5 min; 1 U enzyme added; 94‡C for 1^1.5 min; 54^56‡C for 1 min
(depending on the primer pair); 72‡C for 1^1.5 min; ¢nal incubation
at 72‡C for 10 min with the main section repeated 25^30 times. Four
independent NA1-NA3/NA2-NA3 clones from the MAT-LyLu and
three independent NA2-NA3 clones from the AT-2 were sequenced
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and found to be identical to the rat skeletal muscle VGSC (rSkM1)
sequence [10]. Additional PCR primers speci¢c for rSkM1 cDNA
were then designed (see Table 1) and sscDNA was synthesised (using
NA6, NA9, NA11 and NA24 primers, speci¢c for rSkM1) in order to
obtain the full coding sequence of the channel. Combinations of the
sense and anti-sense PCR primers produced a series of overlapping
fragments for each of the cell lines.
All chosen fragments were gel puri¢ed, and either ligated directly
into the pMOS (Amersham pMosBLue T-vector kit) or pGEM vector
(Promega pGEM-T Easy vector system), or kinased and blunt-end
ligated into phosphatased pUC18 at the SmaI site. These were then
used to transform E. coli (pMOSBlue). The fragments were then sub-
jected to automated DNA sequencing along both strands using either
vTaq or Thermo Sequenase (Amersham) £uorescent cycle sequencing
kits and the Vistra DNA 725 automated sequencer. Independent
clones and overlapping DNA fragments were compared to identify
PCR errors. The full MAT-LyLu/AT-2 rSkM1 sequence obtained
has been submitted to GenBank.
2.4. Northern blots
Approximately 20 Wg of mRNA extracted from both AT-2 and
MAT-LyLu cell lines (Qiagen oligotex mRNA extraction kit) were
run on a 1.0% agarose gel containing 10% 10UMOPS (pH 7.0) and
18% formaldehyde. Samples were loaded in a bu¡er containing 62.5%
formamide, 25% formaldehyde, 12.5% 10UMOPS (pH 7.0). Transfer
of RNA from the gel to a positively charged nylon membrane was
then performed overnight, as described in [21]. Blots were cross-linked
by automated exposure to a low dose of ultraviolet radiation (254
nm), and hybridised with a 32P-labelled DNA probe (Promega ‘Ready
Go’ kit) corresponding to the NA8-NA22 region of the AT-2/MAT-
LyLu rSkM1 channel. Prehybridisation and hybridisation steps were
performed at 65‡C in a bu¡er solution (containing 0.25 M Na2HPO4,
0.25 M NaH2PO4, 1 mM EDTA (pH 8.0) and 7% SDS) for 30 min
and overnight, respectively. The blots were washed twice for 15 min at
57‡C with 2USSC/0.1% SDS and twice with 0.2USSC/0.1% SDS for
15 min at 61‡C. Autoradiography was for 92 h at 370‡C with an
intensifying screen. The amount of mRNA required for gel loading
was determined by trial and error.
2.5. In situ hybridisation
The RNA probes used would recognise nucleotide sequences 5970^
6277, 7385^7820, 6807^7302, 6325^6822, 140^669 and 6461^6761
(GenBank numbering) of VGSC K-subunits SkM1, rat brain (RB) I,
RB II, RB III, NaG and Na6, respectively. The construction of the
digoxigenin-substituted riboprobes has already been described and
these probes have previously been utilised to localise VGSC mRNAs
in a variety of excitable and non-excitable cells [4,21,22]. Cells were
processed and in situ hybridisation performed exactly as in [21], ex-
cept that the hybridisation solution contained only 0.25 ng/Wl of
probe, and hybridisation was performed at 54‡C.
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Table 1
PCR primers used to clone and sequence rSkM1 and hSkM1 VGSC K-subunits from the prostate adenocarcinoma cell lines
Primer annealing positions are indicated in parentheses (numbering according to [10,23]).
Table 2
Nucleotide di¡erences in full coding MAT-LyLu/AT-2 rSkM1 cDNA compared with the published rat sequence [10]
Variant name Nucleotide position Amino acid change Structural region
R1 358 (G to A) Val to Ile at 120 N terminus
R2 1194 (G to A) No change (Thr 398) D1: S5^S6
R3 2442 (C to T) No change (Asn 814) ID 2^3
R4 2748 (G to C) Gln to His at 916 ID 2^3
R5 3132 (G to A) No change (Glu 1044) D3: S1
R6 3605 (C to G) Ser to Cys at 1202 D3: S5^S6
R7 3769 (C to G) His to Asp at 1257 D3: S5^S6
R8 3942 (T to C) No change (Asn 1314) ID 3^4
R9 4929 (A to G) No change (Pro 1643) C terminus
R10 5264 (A to G) Asp to Gly at 1755 C terminus
R11 5407 (G to A) Glu to Lys at 1803 C terminus
The ¢rst 19 and the last 15 nucleotides of the full coding sequences are derived from the NA18 and NA9 primers used in PCR reactions and
consequently do not necessarily corrrespond to the original MAT-LyLu/AT-2 rSkM1 sequence.
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3. Results
3.1. Full rSkM1 sequence
The full coding sequences of the VGSC mRNA transcripts
detected in the MAT-LyLu and AT-2 cell lines are identical to
each other. Furthermore, apart from 11 base positions, this is
identical to the published sequence of the rSkM1 channel [10].
The di¡erences found are summarised in Table 2 and illus-
trated in Fig. 1. Most of the sequence changes are located in
the second half of the channel coding region (including all of
the third and fourth transmembrane domains), and most sub-
stitute purine residues. Only one of these 11 nucleotides (R5)
is located in a proposed transmembrane region. Six of the
nucleotide di¡erences (R1, R4, R6, R7, R10 and R11), all
in non-transmembrane regions of the proposed channel struc-
ture, would cause amino acid sequence changes in the channel
protein (Fig. 1 and Table 2). Four of these six substitutions
(R4, R7, R10 and R11) result in charge di¡erences. R7 and
R11 substitute positive for negatively charged residues in the
overall negatively charged channel pore and carboxyl tail (C-
tail) regions, respectively. In contrast, R10 removes a nega-
tively charged residue in the C-tail, and R4 introduces a pos-
itive amino acid in the cytoplasmic linker connecting the sec-
ond and third transmembrane domains.
3.2. Detection of full-length rSkM1 mRNA
As shown in Fig. 2, 32P-labelled probes, generated from a
cDNA template corresponding to the NA8-NA22 region of
the partial sequence, hybridised with an RNA species of ap-
proximately 9 kb in size in both AT-2 and MAT-LyLu
mRNA extracts (lanes A and B), similar to the size of the
signal from the total RNA extract of rat skeletal muscle
(lane C). The size corresponding to all three of the bands
agrees well with the 8.5 kb transcript size previously reported
for rSkM1 [14]. This would indicate that full-length rSkM1
mRNA is present in both cell lines, possibly at a higher level
in the MAT-LyLu cells (Fig. 2).
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Fig. 1. Schematic representation of the rSkM1 K-subunit, drawn to approximate scale, with channel topology adopted from current VGSC
models. Domains, each containing six transmembrane segments, are numbered I to IV. Amino acid changing nucleotide di¡erences detected in
the MAT-LyLu/AT-2 rSkM1 K-subunit are indicated by crosses and labelled according to Table 2.
Fig. 2. Northern blots of AT-2 (lane A), MAT-LyLu (lane B) and
rat skeletal (lane C) muscle extracts (20 Wg of mRNA for A and B,
and 5 Wg of total RNA for C) exposed for 92 h after hybridisation
with the 32P-labelled rSkM1 DNA probe derived from NA8-NA22.
Hybridisation with a ca. 9 kb transcript was seen in all three lanes.
Positions of RNA molecular weight standards (in kb) are indicated
on the left.
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3.3. Expression pattern of VGSC mRNA
The expression of rSkM1 mRNA was examined in MAT-
LyLu and AT-2 cells by non-radioactive in situ hybridisation
cytochemistry utilising isoform-speci¢c riboprobes. Hybridisa-
tion signal for rSkM1 transcripts was detected in both cell
lines, although greater signal was generally observed in the
MAT-LyLu cells (Fig. 3A,B). However, the MAT-LyLu cells
did not display a uniform level of rSkM1 hybridisation signal;
rather, some cells were intensely labelled while other cells
showed more moderate levels of expression. In the case of
the AT-2 cells, the rSkM1 hybridisation signal was more uni-
form although most cells exhibited much lower levels of ex-
pression. On the other hand, hybridisation signal above back-
ground was inconsistent or not detected when the MAT-LyLu
and AT-2 cells were treated with riboprobes speci¢c for
VGSC mRNAs RB I (Fig. 3C,D), RB II (Fig. 3E,F), RB
III (Fig. 3G,H), NaG/SCL-11 (Fig. 3I,J) and Na6 (Fig. 3K,L).
3.4. Partial SkM1 sequence from human prostate cancer cell
lines
A partial sequence corresponding to the whole of trans-
membrane domain four and the proposed intracellular C-tail
of human skeletal muscle type 1 (hSkM1) VGSC was ob-
tained in the human PC-3 and LNCaP cell line using PCR
primers speci¢c for SkM1 and a cloning strategy like that used
for the 3P end cloning of the rSkM1 channel, described above.
The 3P end of the channel was targeted speci¢cally as this part
of the SkM1 sequence crosses a known intron site [23] and is
considerably di¡erent between rSkM1 and hSkM1 orthologs.
The corresponding sequences in the two cell lines are not
identical but display variations from the hSkM1 sequence as
reported previously [24], being possible natural polymor-
phisms [25]. Thus, PC-3 hSkM1 possesses an adenine residue
at bp 4616 (all numbering according to [36], and the LNCaP
hSkM1 has an adenine residue at bp 4203, and an adenine or
guanine residue (indicating, perhaps, that more than one allele
of the hSkM1 channel was being expressed) at bp 4946.
4. Discussion
The main conclusions of the present study are three-fold.
(1) Both MAT-LyLu and AT-2 cell lines express VGSC
mRNA, although the channel appears functional only in the
former. (2) In both cells, rSkM1 VGSC mRNA is present. (3)
SkM1 mRNA is similarly expressed in analogous human
prostate cancer cell lines. The present study is also the ¢rst
to demonstrate SkM1 type VGSC mRNA expression in cells
other than skeletal muscle.
4.1. Molecular identity of the rat VGSC(s)
The data obtained from cloning and sequencing, Northern
blots and in situ hybridisation, taken together, are consistent
with expression of full-length rSkM1-type VGSC mRNA in
both the MAT-LyLu and the AT-2 cell lines.
The AT-2 and MAT-LyLu cell lines, both originally derived
from the same prostatic tumour in a Copenhagen rat, possess
VGSC mRNA with identical sequence. The published rSkM1
sequence was derived from an adult male Wistar rat. Di¡er-
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Fig. 3. Detection by in situ hybridisation of VGSC K-subunit
mRNA expression in MAT-LyLu (left column) and AT-2 (right col-
umn) cells. MAT-LyLu cells (A, C, E, G, I, K) and AT-2 cells (B,
D, F, H, J, L) were hybridised with riboprobes speci¢c for VGSC
mRNAs SkM1 (A, B), RB I (C, D), RB II (E, F), RB III (G, H),
NaG/SCL-11 (I, J) and Na6 (K, L). SkM1 mRNA was expressed in
both MAT-LyLu and AT-2 cells, but the hybridisation signal was
substantially greater in MAT-LyLu cells. VGSC mRNAs RB I, RB
II, RB III, NaG/SCL-11 and Na6 were not detected in either MAT-
LyLu or AT-2 cells. KP and LP are Nomarski images of the bright
¢elds shown in K and L, respectively. U600. Bar, 10 Wm.
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ences between the determined MAT-LyLu/AT-2 rSkM1 chan-
nel and the published rSkM1 sequences may, therefore, result
from the di¡erent sources of rat RNA. Alternatively, the se-
quence di¡erences may (i) re£ect natural polymorphisms, like
those identi¢ed in hSkM1 in this study and by other workers
(e.g. [25]), which are thought to have little e¡ect on channel
functionality; and/or (ii) be due to the pathophysiology of the
disease and have functional signi¢cance.
Alignment of all previously cloned and sequenced VGSCs
allows more reasoned speculation as to whether the amino
acid substitutions observed would have functional consequen-
ces. Thus, four of the six amino acid substitutions, generated
by nucleotide changes at R1, R4, R6 and R10 (Table 2 and
Fig. 1), appear to be conservative in that the introduced res-
idues are present at corresponding positions in the other
SkM1 channels sequenced to date (either equine or human).
Indeed, the change at R6 generates a cysteine residue at 1202
which is present at the corresponding position in all other
presently cloned and sequenced vertebrate and invertebrate
VGSCs, apart from Drosophila para. In contrast, changes at
R7 and R11 are more likely to have some e¡ect on rSkM1
properties. R7 introduces an acidic aspartate residue into the
S5^S6 region of the third domain of the channel, 16 amino
acids from the proposed SS2 region. This part of the channel
is thought to act as the ion selectivity ¢lter, and has also been
indicated to be the site of binding of the guanidinium toxins,
TTX and saxitoxin [26,27]. Interestingly, amongst other
VGSCs, aspartate is only present in the corresponding posi-
tion of Na6 and its mouse orthologue, Scn8a; channels which
are proposed to play an essential role in the central nervous
system [28]. R11 substitutes an acidic for a basic residue in the
negatively charged rSkM1 C-tail. The C-tail of VGSCs has
been indicated to play a role in channel activation and inacti-
vation by virtue of its negativity [29]. Both activation and
inactivation kinetics of the MAT-LyLu VGSC di¡er slightly
from those measured for rSkM1 [30], which may be a re£ec-
tion of this change in the primary channel sequence. However,
the glutamate substituted here is not conserved in other se-
quenced SkM1 channels, which may indicate that this residue
does not have a major e¡ect upon channel kinetic properties.
It should be noted, additionally, that activation and/or inac-
tivation kinetics vary widely depending on the expression sys-
tem used [31,32], and can be modulated by factors such as L-
subunit coexpression, degree of post-translational glycosyla-
tion and di¡erent lipid domains [31,33].
Application of 1 WM W-conotoxin (W-CTX) has been found
to have a limited (0^5%) blocking e¡ect on the VGS currents
in MAT-LyLu cells whilst 10 WM W-CTX caused complete
block ([18]; S.P. Fraser, unpublished observations). Only rat
and human SkM1 and eel electroplax VGSCs are suppressed
by W-CTX, being blocked by nM concentrations [32]. It ap-
pears, therefore, that the functional VGSCs present in the
MAT-LyLu cells display pharmacological properties that dif-
fer quantitatively from rSkM1. This may be because rSkM1
VGSC sensitivity to W-CTX is reduced in the MAT-LyLu
cells. Possibly the R6/R7 changes in D3 S5^6 alter the W-
CTX binding site in the channel pore directly, or these
changes in the outer region of the pore indirectly reduce e⁄-
cacy of W-CTX blockage of channel current. Although the
exact location of the W-CTX binding site is unknown, muta-
tions in the ion selectivity ¢lter have been demonstrated to
signi¢cantly a¡ect W-CTX binding [34,35]. Alternatively, novel
folding or glycosylation of the rSkM1 channel in this partic-
ular cell type may account for the reduced toxin e⁄cacy.
4.2. Expression of VGSC mRNA in both MAT-LyLu and
AT-2 cells
MAT-LyLu cells displayed heterogeneity in channel mRNA
expression, with some cells more intensely labelled (by rSkM1
riboprobes) than others (Fig. 3). We have reported previously
that expression of functional VGSCs in MAT-LyLu cells
shows strong heterogeneity, providing an electrophysiological
parallel to these observations [15]. On the other hand, the AT-
2 cells showed more uniform but much lower levels of mRNA
expression.
No evidence for functional VGSC expression has been
found by electrophysiological recording in lowly metastatic
cell lines modelling prostate cancer (AT-2 from rat [15];
LNCaP from human [17]). It was surprising, therefore, that
in the present study we have found expression of VGSC
mRNA in the AT-2 cells, albeit at low levels (Fig. 3). This
apparent contradiction could be due to the following. (a)
Normal channel proteins may be present in the AT-2 cell
line but at a sub-threshold density, below that required for
electrophysiological detection. (b) The VGSC in the AT-2
cells may be non-functional. This could be due to several
possible reasons, including (i) mutation(s) in non-coding re-
gions of the AT-2 channel mRNA; and (ii) existence of post-
translational mechanism(s) in the AT-2 cell line non-condu-
cive to functional rSkM1 production. Several studies indeed
have demonstrated that functional expression of VGSCs can
be directly a¡ected by post-translational modi¢cations, such
as glycosylation [36], phosphorylation [37], and L-subunit co-
expression [38].
4.3. Relevance of the Dunning model system to human prostate
cancer
The ¢nding that SkM1 mRNA is expressed in both rat and
human prostate cancer cell extends the evidence that the Dun-
ning system of highly and lowly metastatic cell lines is a viable
model of human prostate cancer. Importantly, species boun-
daries aside, such consistency is striking considering that the
two human cell lines were obtained originally from unrelated
sources: PC-3 cells were derived from a bone marrow meta-
stasis of a prostatic adenocarcinoma from a 62-year-old Cau-
casian [39], whilst the LNCaP cell line was initiated from a
supraclavicular lymph node from a 50-year-old Caucasian
with hormone-refractory prostate cancer [40]. Further work
is required to determine the possible functional signi¢cance
of the conserved expression of skeletal muscle type VGSC in
rat and human prostate cancer cells.
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